HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction

Journal of Internal Medicine

Volumn 270, Issue 3, 2011, Pages 245-253

  Andrassy, M ^a   Volz, H C ^a   Riedle, N ^a   Gitsioudis, G ^a   Seidel, C ^a   Laohachewin, D ^a   Zankl, A R ^a   Kaya, Z ^a   Bierhaus, A ^b   Giannitsis, E ^a   Katus, H A ^a   Korosoglou, G ^a  

^a Departments of Cardiology   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acute coronary syndrome; HMGB1 protein; Magnetic resonance imaging

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE MARKER; FEMALE; FUNCTIONAL ASSESSMENT; HEART EJECTION FRACTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART SCINTISCANNING; HOST RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ADULT; AGED; BIOLOGICAL MARKERS; CONTRAST MEDIA; CREATINE KINASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART CONDUCTION SYSTEM; HMGB1 PROTEIN; HUMANS; INFLAMMATION; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; STROKE VOLUME; TIME FACTORS; TROPONIN T; VENTRICULAR FUNCTION, LEFT;

EID: 80051553550     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02369.x     Document Type: Article

References (39)

1. Zijlstra F, Patel A, Jones M et al. Clinical characteristics and outcome of patients with early (<2h), intermediate (2-4h) and late (>4h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J 2002; 23: 550-7.
2. Harrison JK, Califf RM, Woodlief LH et al. Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Analysis of determinants of improvement. The TAMI Study Group. Circulation 1993; 87: 1531-41.
3. Heymans S, Hirsch E, Anker SD et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11: 119-29.
4. Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res 2009; 81: 474-81.
5. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91: 988-98.
6. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103: 2055-9.
7. Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-23.
8. Aukrust P, Ueland T, Lien E et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83: 376-82.
9. Agnoletti L, Curello S, Bachetti T et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation 1999; 100: 1983-91.
10. Rauchhaus M, Doehner W, Francis DP et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-7.
11. Yin WH, Chen JW, Jen HL et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004; 147: 931-8.
12. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007; 220: 35-46.
13. Andrassy M, Volz HC, Igwe JC et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008; 117: 3216-26.
14. Goldstein RS, Gallowitsch-Puerta M, Yang L et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006; 25: 571-4.
15. Cirillo P, Giallauria F, Pacileo M et al. Increased high mobility group box-1 protein levels are associated with impaired cardiopulmonary and echocardiographic findings after acute myocardial infarction. J Card Fail 2009; 15: 362-7.
16. Korosoglou G, Labadze N, Hansen A et al. Usefulness of real-time myocardial perfusion imaging in the evaluation of patients with first time chest pain. Am J Cardiol 2004; 94: 1225-31.
17. Kim RJ, Wu E, Rafael A et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343: 1445-53.
18. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
19. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
20. Sun M, Dawood F, Wen WH et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 2004; 110: 3221-8.
21. Kohno T, Anzai T, Naito K et al. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res 2009; 81: 565-73.
22. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004; 94: 1543-53.
23. Maekawa Y, Anzai T, Yoshikawa T et al. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling. J Am Coll Cardiol 2002; 39: 241-6.
24. Suzuki S, Takeishi Y, Niizeki T et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008; 155: 75-81.
25. Bahrami H, Bluemke DA, Kronmal R et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008; 51: 1775-83.
26. Volz HC, Kaya Z, Katus HA, Andrassy M. The role of HMGB1/RAGE in inflammatory cardiomyopathy. Semin Thromb Hemost 2010; 36: 185-94.
27. Wilke N, Jerosch-Herold M, Wang Y et al. Myocardial perfusion reserve: assessment with multisection, quantitative, first-pass MR imaging. Radiology 1997; 204: 373-84.
28. Korosoglou G, Haars A, Michael G et al. Quantitative evaluation of myocardial blush to assess tissue level reperfusion in patients with acute ST-elevation myocardial infarction: incremental prognostic value compared with visual assessment. Am Heart J 2007; 153: 612-20.
29. Korosoglou G, Osman NF, Dengler TJ et al. Strain-encoded cardiac magnetic resonance for the evaluation of chronic allograft vasculopathy in transplant recipients. Am J Transplant 2009; 9: 2587-96.
30. Giallauria F, Cirillo P, Lucci R et al. Autonomic dysfunction is associated with high mobility group box-1 levels in patients after acute myocardial infarction. Atherosclerosis 2010; 208: 280-4.
31. Volz HC, Seidel C, Laohachewin D et al. HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res Cardiol 2010; 105: 805-20.
32. Tzeng HP, Fan J, Vallejo JG et al. Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes. Am J Physiol Heart Circ Physiol 2008; 294: H1490-6.
33. Huang Y, Yin H, Han J et al. Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 2007; 7: 799-808.
34. Limana F, Germani A, Zacheo A et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res 2005; 97: e73-83.
35. Kitahara T, Takeishi Y, Harada M et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc Res 2008; 80: 40-6.
36. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-42.
37. Xu H, Su Z, Wu J et al. The alarmin cytokine, high mobility group box 1, is produced by viable cardiomyocytes and mediates the lipopolysaccharide-induced myocardial dysfunction via a TLR4/phosphatidylinositol 3-kinase {gamma} pathway. J Immunol 2010; 184: 1492-8.
38. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009; 52: 2251-63.
39. Takahashi M. High-mobility group box 1 protein (HMGB1) in ischaemic heart disease: beneficial or deleterious? Cardiovasc Res 2008; 80: 5-6.